Introduction
Methods
Search methods
Criteria for inclusion
Evaluation of outcome data
Statistical analysis
Results
Description of included studies
Study | Patient characteristics | Aspirin | IVIG | Corticosteroid | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total patients | Therapy group | Sex (male %) | Age (year) | Therapy day | mg/kg per day | g/kg per dose | No. of doses | Drug preparation | Dosage (mg/kg per day) | Duration of therapy (days) | |
Newburger et al. [17] | 199 | 101 | 62 | 2.9 | 10 | 80–100 | 2 | 1 | IVMP | 30 | 1 |
Inoue et al. [8] | 178 | 90 | 57.3 | 4.5 | 9 | 30 | 1 | 2 | Pred | 2 | 3 |
Okada et al. [21] | 32 | 14 | 56.3 | 2.8 | 9 | 30 | 1 | 2 | Pred | 2 | 3 |
Sundel et al. [25] | 39 | 18 | 69 | 10 | 20–25 | 2 | 1 | IVMP | 30 | 1 | |
Okada et al. [20] | 94 | 62 | 77.4 | 2.8 | 6 | 30 | 2 | 1 | IVMP | 30 | 1 |
Jibiki et al. [10] | 92 | 46 | 48.9 | 2.3 | 7 | 30 | 0.4 or 0.5 | 4–5 | Dex | 0.3 | 3 |
Shinohara et al. 1 [22] | 212 | 170 | – | – | 9 | 30 | 0 | 0 | Pred | 2 | Defervescence |
Shinohara et al. 2 [22] | 87 | 62 | – | – | 9 | 30 | 0.2 or 0.4 | 5 | Pred | 2 | Defervescence |
Study | Patient characteristics | Aspirin | IVIG | Corticosteroid | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total patients | Therapy group | Sex (male %) | Age (year) | Therapy day | mg/kg per day | g/kg per dose | No. of doses | Drug preparation | Dosage (mg/kg per day) | Duration of therapy (days) | |
Ogata S et al. [19] | 27 | 14 | – | 2.5 | 9 | 30 | 2 | 1 | IVMP | 30 | 3 |
Miura et al. [14] | 15 | 7 | 66.7 | 2.6 | 9 | – | 2 | 1 | IVMP | 30 | 3 |
Hashino et al. [7] | 17 | 9 | – | 6.3 | 9 | 30 | 1 | 1 | IVMP | 20 | 3 |
Furukawa et al. [6] | 63 | 44 | 54 | 2.4 | 8 | 30 | 1–2 | 3 | IVMP | 30 | 3 |